Indaptus Therapeutics enters amended ATM equity distribution agreement for up to $100 million common stock offering

• Indaptus Therapeutics entered an amended, restated at-the-market sales agreement with H.C. Wainwright for up to USD 100 million of common stock.
• Shares may be sold from time to time through Wainwright as sales agent at prevailing market prices, subject to company-set daily size limits.
• Sales under the new program start fresh versus the prior 2022 ATM; earlier sales do not count toward the USD 100 million cap.
• Offering is tied to the company’s Form S-3 shelf registration statement, with a new prospectus supplement dated Aug. 31, 2026.
• Company can suspend sales at any time; Wainwright has no obligation to buy shares as principal absent a separate terms agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-040926), on September 01, 2026, and is solely responsible for the information contained therein.